Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Moderna also announced a $3 billion share repurchase plan

Moderna Beats Earnings Estimates. The Stock Is Down.

Moderna Inc. MRNA, -6.37% beat earnings and revenue expectations for the fourth quarter of 2021 after announcing Thursday that its COVID-19 vaccine brought in nearly $7 billion in product sales during the final three months of the year. Moderna had a profit of $4.8 billion, or $11.29 per share, in the fourth quarter of 2021, after reporting a loss of $272 million, or 69 cents per share, in the fourth quarter of 2020.

Moderna's COVID-19 shot generated $6.9 billion in sales in the fourth quarter

Moderna Inc on Thursday raised its full-year sales forecast for its COVID-19 vaccine by 2.7% to $19 billion, as it seeks to ramp up manufacturing following production problems last year.

Moderna raises 2022 COVID vaccine sales forecast to $19 billion

Moderna beat on its top and bottom lines, reporting earnings per share of $11.29 and revenue of $7.2 billion.

Moderna expects at least $19 billion in Covid vaccine sales in 2022, reports big fourth-quarter earnings beat

Q4 2021 revenues of $7.2 billion; GAAP net-income of $4.9 billion and GAAP diluted EPS of $11.29 Full year 2021 revenues of $18.5 billion; GAAP net-income of $12.2 billion and GAAP diluted EPS of $28.29 Moderna increased its 2022 signed advance purchase agreements to approximately $19 billion, with additional signed options of approximately $3 billion; numerous discussions ongoing with governments for the fall of 2022 and 2023 Moderna received full U.S. FDA approval for COVID-19 vaccine, Spikevax Moderna announces new bivalent booster candidate (mRNA-1273.214) combining Omicron-specific booster candidate (mRNA-1273.529) and the Moderna COVID-19 vaccine (mRNA-1273) Company now has 44 programs in development Moderna announces a new $3 billion share repurchase plan CAMBRIDGE, MA / ACCESSWIRE / February 24, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today reported financial results and provided business updates for the fourth quarter of fiscal year 2021. "Spikevax is now approved in more than 70 countries around the world protecting hundreds of millions of people and real-world evidence from multiple independent studies has confirmed its strong effectiveness," said Stéphane Bancel, Chief Executive Officer of Moderna.

Moderna Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides Business Updates

AstraZeneca

Novavax

Pfizer

Here are four pharma stocks that looks attractive for the long-term. Deep product development pipelines will ensure steady revenue and cash flow growth.

4 Pharma Stocks to Buy Even if the Pandemic Ends

Moderna Inc (NASDAQ: MRNA) shares are trading higher by 9.7% at $149.11 after the company reported better-than-expected fourth-quarter EPS and sales results and announced a new $3 billion buyback. Moderna reported quarterly earnings of $11.29 per share which beat the analyst.

What's Going On With Moderna Shares Today?

Moderna Inc (NASDAQ: MRNA) reports a Q4 EPS of $11.29, a turnaround from an EPS loss of $(0.69) a year ago, beating the consensus estimate of $9.90. The Company clocked Q4 revenues of $7.21 billion compared to just $571 million a year ago, beating the consensus of $6.79 billion.

Moderna Beats On Q4 Earnings, Announces $3B Buyback; Expects ~$19B In FY22 COVID-19 Vax Sales

Moderna stock fell 6% despite the bullish projection, pushing shares down nearly 72% below their August all-time high.

Moderna Stock Crash Worsens Even After Morgan Stanley Says Flu Vaccine Results Could Boost Shares

Medtronic

Regeneron Pharmaceuticals

Teladoc

Can these top health care stocks be the way to go amidst all the uncertainty in the stock market now?

Best Stocks To Invest In Right Now? 5 Health Care Stocks In Focus

A new COVID-19 vaccine option could be on its way to the market.

Why Moderna Stock Is Falling Today

The shares of Moderna Inc (NASDAQ:MRNA) are down 4.7% at $138.18 this afternoon, as investors gear up for the vaccine company's fourth-quarter earnings report, due out before the open tomorrow, Feb.  24.

Options Bears Target Moderna Stock Ahead of Earnings Report

Aerie Pharmaceuticals

Emergent BioSolutions

Editas Medicine

Vir Biotechnology

Let us take a look at five biotech/drug companies, namely, MRNA, EDIT, VIR, EBS and AERI, which are due to release their quarterly results on Feb 24.

Drug/Biotech Stocks' Q4 Earnings on Feb 24: MRNA, EBS & More

Booking Hlds

Lemonade

Planet Fitness

Skillz

Will these 5 companies break out, or break down, after they report earnings this week?

5 Intriguing Earnings Charts

The CDC said males ages 12- to 39-years-old should consider waiting 8 weeks between the first and second doses of Pfizer and Moderna's vaccines.

CDC says waiting longer between Pfizer, Moderna doses may reduce rare myocarditis risk for younger men

Moderna stock fell 4% despite the bullish projection, pushing shares down nearly 72% below their August all-time high.

Moderna Stock Crash Steepens—But Expert Declares Incoming Flu Vaccine Results Could Show ‘Superiority'

Thermo Fisher Scientific

Moderna Inc. MRNA, -0.53% and life-sciences company Thermo Fisher Scientific Inc. TMO, -1.35% said Wednesday they have entered a long-term agreement to collaborate on large-scale manufacturing of the former's COVID-19 vaccine dubbed Spikevax and other therapies based on its mRNA technology. In a joint statement, the companies said they have already been working together to support Moderna's pipeline with Thermo Fisher providing clinical research and contract manufacturing services, including aseptic fill-finish services and packaging of the COVID vaccine.

Moderna and Thermo Fisher enter long-term agreement on large-scale manufacturing of COVID vaccine

CAMBRIDGE, Mass., & WALTHAM, Mass.--(BUSINESS WIRE)--Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today announced a 15-year strategic collaboration agreement to enable dedicated large-scale manufacturing in the U.S. of Spikevax®, Moderna's COVID-19 vaccine, and other investigational mRNA medicines in its pipeline. “Thermo Fisher continues to be a

Moderna and Thermo Fisher Scientific Announce Long-Term Strategic Collaboration

With Moderna trading at such a low valuation and generating a lot of cash its shares should move higher if anything positive is announced Thursday morning.

Moderna's Stock Setup To Recoup At Least Some Of Its $153 Billion In Lost Market Cap

American Airlines

Tesla

Select analysts and investment banks believe these widely owned stocks will plunge.

3 Ultra-Popular Stocks That Can Plummet Up to 65%, According to Wall Street

Moderna has a commercial footprint in 56 countries across the world through direct presence and distributors and plans expansion in ten additional markets in 2022 Moderna also supplies the Company's COVID-19 vaccine to 92 Gavi COVAX Advance Market Commitment (AMC) low- and middle-income countries through GAVI, the Vaccine Alliance agreement CAMBRIDGE, MA / ACCESSWIRE / February 22, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines today announced a distribution service agreement with Adium Pharma S.A., a leading private Latin American pharmaceutical company, to support the commercialization of the Moderna COVID-19 vaccine, Spikevax across Latin America.

Moderna Expands Global Footprint Through Commercial Partnership with Adium in Latin America

MRNA stock has fallen into the buy zone, providing a prime opportunity as Moderna develops and commercializes multiple vaccine products. The post Moderna Offers Deep Value as Drug Pipeline Flows Fast appeared first on InvestorPlace.

Moderna Offers Deep Value as Drug Pipeline Flows Fast

Shares of Moderna Inc. MRNA, +2.82% gained 3.0% in trading on Monday after the company said it began a Phase 3 clinical trial evaluating its respiratory syncytial virus vaccine candidate. RSV is a common, seasonal respiratory virus that causes cold symptoms; it is more likely to become serious in children and older adults.

Moderna's stock gains 3% as it moves forward with Phase 3 clinical trial for RSV vaccine candidate

Moderna Inc. ( MRNA , Financial) announced on Friday that it is expanding its mRNA pipeline with three new development programs.

Moderna Expands Its mRNA Pipeline

Endorsement to proceed given by the independent Data and Safety Monitoring Board based on preliminary Phase 2 safety and tolerability data Moderna expects to enroll approximately 34,000 participants in multiple countries RSV causes severe disease burden among older adults and young children; there is no approved vaccine to prevent RSV CAMBRIDGE, MA / ACCESSWIRE / February 22, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the Data and Safety Monitoring Board (DSMB) for the RSV program has endorsed the start of the Phase 3 portion of the pivotal clinical study of mRNA-1345, the Company's Respiratory Syncytial Virus (RSV) vaccine candidate, in adults 60 years and older. The DSMB's endorsement comes after independent review of preliminary Phase 2 data, which suggest that the vaccine has an acceptable safety profile in older adults at the selected dose.

Moderna Initiates Phase 3 Portion of Pivotal Trial for mRNA Respiratory Syncytial Virus (RSV) Vaccine Candidate, Following Independent Safety Review of Interim Data

News for Moderna Stock (MRNA)